A recombinant scFv-FasLext as a targeting cytotoxic agent against human Jurkat-Ras cancer

Table 2 Highly cytotoxic cc49scFv-FasL _ext eradicated Jurkat-Ras cancer in SCID mice ^a

Cells injected on day 0	Treatment begins on	# mice treated	Tumor incidence	# tumor-free mice at the end of the treatment^b
(40-50)×10⁶ Jk-Ras Control	Day 1-2	7	6 at 4-6 wk later	1
(40-50)×10⁶ Jk-Ras Test	Day 1-2	8	0 at 4-6 wk later	8
20×10⁶ Jk-Ras Control	Day 6	4	4 at 4-6 wk later	0
20×10⁶ Jk-Ras Test	Day 6	5	1 at 4-6 wk later	4

^aSCID mice (>14 weeks old) of both sexes were transferred by IP injection of Jurkat-Ras (Jk-Ras) or HeLa at day 0. Treatment started at indicated times by IP injection of cc49scFv-FasL_ext-containing supernatants (2 μg/ml) or concentrated L6scFv-FasL_ext (5-10 μg/ml) as described in the “Methods”.
^bTwo months after the end of the treatment, the survived mice still lived without any indication of toxicity induced by the treatment. Normal liver appearance was observed when survived mice were euthanized later.

ISSN: 1423-0127